(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit. The error also appeared in an earlier version of the story.) (Reuters) - I ...

Northern TK Venture filed a claim against Daiichi Sankyo saying the latter prevented NTK from proceeding with its open offer. IHH Healthcare is seeking compensation of up to $1.7b (₹109.3b) from ...

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...

Disclaimer: This article has been developed and funded by Daiichi Sankyo. Daiichi Sankyo has more than 120 years of experience and scientific expertise. In 2019, they entered the oncology market ...

Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1 ...

Following this approval for Enhertu in the U.S., AstraZeneca is due $175 million as a milestone payment to Daiichi Sankyo. Daiichi Sankyo recognizes Enhertu sales in the U.S. AstraZeneca reports ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

Daiichi Sankyo’s Q3 FY2024 results reflect strong performance in oncology, driven by ENHERTU’s market leadership and robust sales growth across regions. Despite regulatory delays for Datroway ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...